Dataset Information

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

ABSTRACT: As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.

SUBMITTER: Lyke KE

PROVIDER: S-EPMC10336079 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

Lyke Kirsten E KE Atmar Robert L RL Dominguez Islas Clara C Posavad Christine M CM Deming Meagan E ME Branche Angela R AR Johnston Christine C El Sahly Hana M HM Edupuganti Srilatha S Mulligan Mark J MJ Jackson Lisa A LA Rupp Richard E RE Rostad Christina A CA Coler Rhea N RN Bäcker Martín M Kottkamp Angelica C AC Babu Tara M TM Dobrzynski David D Martin Judith M JM Brady Rebecca C RC Frenck Robert W RW Rajakumar Kumaravel K Kotloff Karen K Rouphael Nadine N Szydlo Daniel D PaulChoudhury Rahul R Archer Janet I JI Crandon Sonja S Ingersoll Brian B Eaton Amanda A Brown Elizabeth R ER McElrath M Juliana MJ Neuzil Kathleen M KM Stephens David S DS Post Diane J DJ Lin Bob C BC Serebryannyy Leonid L Beigel John H JH Montefiori David C DC Roberts Paul C PC

NPJ vaccines 20230711 1

As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (D ...[more]

PMID: 37433788

Similar Datasets

Project description:The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant spike [rS] protein + 50 µg Matrix-M™ adjuvant; Novavax, Gaithersburg, MD) was evaluated to determine induction of cross-reactive antibodies to variants of concern. A phase II randomized study (NCT04368988) recruited participants in Australia and the United States to assess a primary series of NVX-CoV2373 followed by two booster doses (third and fourth doses at 6-month intervals) in adults 18-84 years of age. The primary series was administered when the SARS-CoV-2 ancestral strain was prevalent and the third and fourth doses while the Alpha and Delta variants were prevalent in AUS and US. Local/systemic reactogenicity was assessed the day of vaccination and for 6 days thereafter. Unsolicited adverse events (AEs) were reported. Immunogenicity was measured before, and 14 days after, fourth dose administration, using anti-spike serum immunoglobulin G (IgG) and neutralization assays against ancestral SARS-CoV-2 strain and Omicron sublineages. Among 1283 enrolled participants, 258 were randomized to receive the two-dose primary series, of whom 104 received a third dose, and 45 received a fourth dose of NVX-CoV2373. The incidence of local/systemic reactogenicity events increased after the first three doses of NVX-CoV2373 and leveled off after dose 4. Unsolicited AEs were reported in 9 % of participants after dose 4 (none of which were severe or serious). Anti-rS IgG levels and neutralization antibody titers increased following booster doses to a level approximately four-fold higher than that observed after the primary series, with a progressively narrowed gap in response between the ancestral strain and Omicron BA.5. A fourth dose of NVX-CoV2373 enhanced immunogenicity for ancestral and variant SARS-CoV-2 strains without increasing reactogenicity, indicating that updates to the vaccine composition may not be currently warranted.

Dataset Information

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

Publications

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets